Ongoing
R01 CA200994 (PI: Miller) 04/01/2017 – 03/31/2027
NIH/NCI $ 243,095 direct costs per year
Project: A precision medicine basis for estrogen therapy for advanced breast cancer.
Role: PI
R01 CA267691 (PI: Miller) 01/01/2022 – 12/31/2027
NIH/NCI $ 231,432 direct costs per year
Project: Uncovering the basis and implications of lineage plasticity in breast cancer.
Role: PI
R01 CA262232 (PI: Miller) 07/04/2022 – 06/30/2027
NIH/NCI $ 234,138 direct costs per year
Project: Therapeutically leveraging metabolic vulnerabilities in breast cancer.
Role: PI
Diversity Supplement to support junior faculty member 07/01/2023 – 06/30/2025
$ 179,830 direct costs per year
Our Patient Project (co-PIs: Chaudhary, Miller, Jorns) 03/01/2024 –2/29/2028
Medical College of Wisconsin Cancer Center $ 162,500 direct costs per year
Project: Molecular analyses to identify pathways of endocrine resistance
following short-term neoadjuvant endocrine treatment in patients
with hormone receptor-positive HER2-negative breast cancer.
Role: Co-PI
Pilot Project Grant (co-PIs: Miller, Chamberlin) 06/01/2021 – open
Norris Cotton Cancer Center Early-Phase Trials Program $ 150,000 total direct costs
Project: Phase II study of Neoadjuvant ArOMatase Inhibitor therapy for ER+ breast cancer (NAOMI).
Role: Co-PI changed to Co-Investigator
Pilot Project Grant (PI: Schwartz) 03/13/2023 – open
Dartmouth Cancer Center Early-Phase Trials Program $ 50,000 total direct costs
Project: Phase II study of estradiol therapy to target ER-mutant and ER-wild-type ER+ metastatic or advanced breast cancer (ESTHER)
Role: PI changed to Co-Investigator
Pilot Project Grant (PI: Tafe) 02/01/2022 – open
Dartmouth Cancer Center Early-Phase Trials Program $ 50,000 total direct costs
Project: CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth (CATRINA).
Role: PI changed to Co-Investigator
Pilot Project Grant (PI: Chamberlin) 03/13/2023 – open
Dartmouth Cancer Center Early-Phase Trials Program (no salary) $ 50,000 total direct costs
Project: Genetically-informed therapy for ER+ breast cancer in a
post-CDK4/6 inhibitor setting: a Phase II umbrella study (GERTRUDE).
Role: PI changed to Co-Investigator
Pilot Project Grant (PI: Chamberlin) 05/01/2023 – open
Dartmouth Cancer Center Early-Phase Trials Program (no salary) $ 300,000 total direct costs
Project: Phase 1b study of olaparib and estradiol in advanced ER+ breast cancer (PHOEBE)
Role: PI changed to Co-Investigator
Completed
Pilot Project Grant (PI: Miller) 08/01/2014 – 07/26/2023
Norris Cotton Cancer Center Early-Phase Trials Program $ 100,000 total direct costs
Project: Alternating estradiol and anti-estrogen therapies to prevent disease progression in advanced ER+/HER2- breast cancer.
Role: PI
P30 CA023108 (PI: Leach) 09/04/2019 – 07/26/2023
Norris Cotton Cancer Center Support Grant
Role: Co-Director of Cancer Biology and Therapeutics Research Program
Big Ideas Grant (PI: Miller) 01/21/2022– 07/20/2023
Norris Cotton Cancer Center $ 150,000 total direct costs
Project: Metabolic vulnerabilities in breast cancer.
Role: PI
Research Project Grant (co-PIs: Pattabiraman, Miller) 06/01/2021 – 05/31/2023
METAvivor $ 47,500 direct costs per year
Project: Differentiation therapy for metastatic breast cancer.
Role: Co-PI
Research Grant (PI: Miller, transferred from Pattabiraman 05/20/2022) 10/11/2020– 10/10/2022
Eisai Pharmaceuticals $ 62,268 total direct costs
Project: Utility of Eribulin
Role: PI
R01 CA211869 (PI: Miller) 09/04/2017 – 08/31/2022
NIH/NCI $ 228,750 direct costs per year
Project: Timing is everything: applications in precision oncology for ER+ breast cancer.
Role: PI
Diversity Supplement to support PhD student 09/01/2019 – 08/31/2022
$52,432 direct costs per year
R33 CA225458 (PI: Kettenbach) 07/01/2019 – 06/30/2022
NIH/NIGMS $ 239,661 direct costs per year
Project: Activity-based profiling of phosphoprotein phosphatases in cancer using mass spectrometry-based proteomics.
Role: Co-Investigator
Investigator-initiated Phase 0 clinical study (Co-PIs: Miller, Phillips) 06/01/2017– 04/30/2022
Norris Cotton Cancer Center Early-Phase Trials Program (no salary) $ 32,748 total direct costs
Project: Metformin pharmacology in human cancers.
Role: Co-PI
Investigator-initiated Phase I clinical study (PI: Schwartz) 10/01/2015 – 12/31/2020
Takeda Pharmaceuticals $ 258,386 total contracted costs;
Project: Phase 1 study of combination of MLN9708 and study terminated after accrual
Fulvestrant in patients with advanced ER+ breast cancer. of 9 subjects.
Role: Co-Investigator
Research Grant (PI: Miller) 11/01/2018 – 10/31/2019
Foundation for Women’s Wellness $ 25,000 total direct costs
Project: Eradicating dormant breast cancer cells to prevent tumor recurrence.
Role: PI
Pilot Project Grant (PI: Miller) 03/01/2018 – 02/27/2019
Part of NIGMS P20 GM113132 $25,000 total direct costs
(iTarget: Institute for Biomolecular Targeting COBRE; PI: Madden)
Project: Apoptotic priming in triple-negative breast and ovarian cancers.
Role: PI
Project-Level Initiative 02/11/2018 – 06/30/2019
Norris Cotton Cancer Center $25,000 total direct costs
Project: Identifying pan-cancer gene expression signatures of drug sensitivity.
Role: PI
Pilot Project Grant (Co-PIs: Tomlinson, Miller) 01/01/2018 – 12/31/2018
Prouty / Norris Cotton Cancer Center $ 50,000 total direct costs
Project: AHR Inhibition Blocks the Diet-Gut Microbiota-Obesity Axis to Reduce Breast Tumor Burden.
Role: Co-PI
V Scholar Award (PI: Kettenbach) 11/01/2016 – 10/31/2018
The V Foundation
Project: Activity-based profiling of protein phosphatases in cancer.
Role: Co-investigator
CCR1533084 (PI: Miller) 07/01/2015– 06/30/2018
Career Catalyst Research Grant $ 360,000 total direct costs
Susan G. Komen
Project: Estrogen receptor reactivation for treatment of advanced breast cancer.
Role: PI
Investigator-initiated Phase I clinical study (PI: Schwartz) 04/01/2017 – 03/01/2019
Takeda Pharmaceuticals $ 404,781 total contracted costs;
Project: Phase 1b neoadjuvant run-in study with TAK-228 study terminated prior to subject
followed by Letrozole/TAK-228 in women with high-risk accrual.
ER+/HER2- breast cancer.
Role: Co-Investigator
Pilot Project Grant (Co-PIs: Mierke, Miller) 01/01/2017 – 06/30/2018
Prouty / Norris Cotton Cancer Center $ 50,000 total direct costs
Project: Identification of novel inhibitors of Rac1.
Role: Co-PI
Multi-PI Initiative Seed Funding (PI: Miller) 11/01/2015 – 10/31/2017
Norris Cotton Cancer Center $ 100,000 total direct costs
Program: Development and management of early-stage breast cancer. for 4 projects
Role: Program Initiator, Co-Leader, and Project #4 PI
Pilot Project Grant (Co-PIs: Diamond, Miller) 10/01/2016 – 04/30/2017
Prouty / Norris Cotton Cancer Center $ 50,000 total direct costs
Project: An image-guided drug delivery platform for precision medicine in cancer.
Role: Co-PI
Pilot Project Grant (Co-PIs: Kettenbach, Miller) 10/01/2015 – 09/30/2016
Prouty / Norris Cotton Cancer Center $ 50,000 total direct costs
Project: Development of a “BRCA-like” protein signature for
identification of triple-negative breast cancers with homologous recombination DNA repair deficiency.
Role: Co-PI
Investigator-initiated Phase I clinical study (PI: Fadul, Univ. of Virginia) 04/01/2016 – 03/31/2019
Novartis Pharmaceuticals
Project: Early-phase study to assess tumor pharmacokinetics and efficacy of the CDK4/6 inhibitor ribociclib (LEE011) in patients with recurrent glioblastoma or anaplastic glioma.
Role: Co-Investigator
Research Grant (PI: Miller) 07/01/2015 – 06/30/2017
The Mary Kay Foundation $ 86,958 total direct costs
Project: Mechanisms underlying dormancy in ER+ breast cancer.
Role: PI
RSG-13-292-01-TBE (PI: Miller) 07/01/2013 – 06/30/2017
American Cancer Society $ 600,000 total direct costs
Project: Targeting PI3K and ER pathways in antiestrogen-resistant breast cancer
Role: PI
K99 CA142899 (PI: Miller) 09/03/2010 – 07/31/2015
R00 CA142899 $ 729,620 total direct costs
NIH/NCI
Project: The effects of PTEN on tyrosine kinase signaling in breast cancer.
Role: PI
Research Grant (Co-PIs: Ronan, Miller) 07/01/2014 – 12/31/2016
The Hitchcock Foundation $ 30,000 total direct costs
Project: Pilot study to develop circulating tumor DNA in cerebrospinal fluid as an early biomarker of leptomeningeal carcinomatosis in patients with metastatic solid tumor cancer.
Role: Co-PI
Clinical Research Pilot Grant (Co-PIs: Miller, Chamberlin) 01/01/2013 – 07/31/2015
The Hopeman Foundation / Norris Cotton Cancer Center $ 46,155 total direct costs
Project: Plasma DNA as a surrogate for tumor biopsy to identify tumor genetic alterations in patients with advanced breast cancer.
Role: Co-PI
Management of Cancer Grant (PI: Miller) 11/17/2012 – 07/31/2015
Doctors’ Cancer Foundation $ 50,000 total direct costs
Project: Circulating tumor DNA as a biomarker of disease burden and response to cytotoxic therapy.
Role: PI
Pilot Project Grant (PI: Miller) 05/01/2012 – 07/31/2015
Norris Cotton Cancer Center Phase I Program $ 15,000 total direct costs
Project: Circulating tumor DNA as a biomarker of tumor burden and response to cytotoxic therapy.
Role: PI
Research Grant (PI: Miller) 08/01/2012 – 05/01/2014
Piramal Life Sciences, Ltd. $ 22,234 total direct costs
Project: Abrogating endocrine resistance in ER+ breast cancer using P1446, P7170, and PL225B.
Role: PI
Pilot Project Grant (PI: Miller) 01/01/2010 – 12/31/2010
American Cancer Society $ 30,000 total direct costs
via Institutional Research Grant IRG-58-009-50 (to Vanderbilt-Ingram Cancer Center)
Project: The effects of PTEN on tyrosine kinase signaling in breast cancer.
Role: PI
Career Development Award (PI: Miller) 07/01/2009 – 06/30/2010
Vanderbilt-Ingram Cancer Center SPORE in Breast Cancer $ 141,220 total direct costs
via P50 CA098131 (NIH/NCI)
Project: The non-redundant and synergistic effects of PTEN and PI3K mutations in cancer.
Role: PI
Pilot Project Grant (PI: Miller) 06/19/2009 – 11/04/2009
Vanderbilt Institute for Clinical and Translational Research $ 1,977 total direct costs
via Clinical and Translational Science Award (NCATS/NIH)
Project: Analysis of ER-dependent pathways in hormone-independent breast cancer cells.
Role: PI
F32 CA121900 (PI: Miller) 04/11/2007 – 04/10/2009
NIH/NCI $ 100,924 total direct costs
Project: Modulation of aromatase: implications for breast cancer.
Role: PI
F31 NS043033 (PI: Miller) 01/03/2002 – 11/08/2004
NIH/NINDS $ 78,530 total direct costs
Project: Intrabody therapy for Huntington’s disease.
Role: PI